GLP-1 Microdosing

Summary: Microdosing means taking a GLP-1 below the FDA-approved schedule, usually for fewer side effects, lower cost, or maintenance after weight loss. There are no major trials, so the safety and efficacy data simply does not exist.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

GLP-1 microdosing is the off-label practice of taking a GLP-1 receptor agonist at a dose below the FDA-approved schedule. In practice that usually looks like 0.05 to 0.125 mg of semaglutide weekly instead of the labeled 0.25 mg start, or staying on a 0.25 mg starter dose indefinitely rather than titrating up to 2.4 mg. Some people stretch the interval instead, injecting every 10 to 14 days. None of these regimens were tested in the trials that got these drugs approved.

This page lays out what microdosing actually means, who is doing it and why, what the evidence does and does not say, and the trade-offs to weigh before you ask a prescriber for a sub-label dose.

What microdosing actually means

There is no formal medical definition. Most clinicians use the term for any of three patterns:

• Sub-starter doses. Semaglutide labeled to start at 0.25 mg weekly. A microdose protocol might begin at 0.05 or 0.125 mg and inch up by 0.05 mg every four weeks. Tirzepatide labeled to start at 2.5 mg. A microdose protocol might begin at 1.0 to 1.5 mg.
• Indefinite starter dose. The patient stays on the lowest approved step forever instead of escalating. For Ozempic that is 0.25 mg weekly. For Zepbound it is 2.5 mg weekly. The label calls these doses initiation, not maintenance.
• Extended interval. The patient takes a normal dose but spaces injections out. Every 10 days, every two weeks, sometimes monthly. This is the strategy showing up in recent case series for post-weight-loss maintenance.

Why people microdose

Three motivations dominate the conversation.

Side effects. Nausea, vomiting, constipation, and diarrhea are dose dependent. The full label-strength titration causes GI symptoms that drive a meaningful percentage of patients to quit. A lower dose typically means a milder side effect profile, sometimes none at all.

Cost. Without insurance, brand semaglutide and tirzepatide run roughly $500 to $1,300 per month. Compounded GLP-1 from a 503A pharmacy can be a fraction of that, and a microdose stretches whatever supply you have. A 5 mg vial dosed at 0.125 mg weekly lasts 40 weeks. Dosed at 0.5 mg, the same vial lasts 10 weeks.

Maintenance after weight loss. This is the most clinically defensible use case. People who lost the weight they wanted at standard doses, then face the regain problem when they stop, sometimes drop to a fraction of their original dose to hold the loss. A 2026 case series in Obesity from Mitch Biermann at Scripps found that patients who spaced their GLP-1 to every 10 to 14 days or longer maintained their weight, body composition, and metabolic improvements ^[4]. The sample was small, the protocol was individualized, and the follow-up was short, but it is the first published signal that reduced-frequency maintenance can hold.

A fourth, less common motive: people who want the appetite quieting effect (the so-called "food noise" reduction) without the weight loss itself. They are not trying to drop pounds, they are trying to switch off intrusive eating thoughts. Reported anecdotally, never studied formally.

Sample microdose regimens

These are the regimens that show up in published guides and clinic protocols. Each one is off-label. Show them to a prescriber, do not run them solo.

The label-approved standard titration for semaglutide goes 0.25 mg for four weeks, then 0.5, 1.0, 1.7, and 2.4 mg ^[1][2]. The label-approved titration for tirzepatide goes 2.5, 5, 7.5, 10, 12.5, and 15 mg, increasing every four weeks as tolerated ^[3]. Microdosing departs from these schedules either at the floor (smaller starting dose), the ceiling (capping the titration early), or the interval (spreading injections out).

What the evidence does and does not show

The honest answer is that microdosing has not been studied in the kind of randomized controlled trial that supported the original approvals. STEP and SURMOUNT enrolled tens of thousands of patients across full titration schedules. No equivalent trial exists for sub-label dosing. What we have instead:

• Dose-response data from the registration trials. Across STEP and SURMOUNT, weight loss tracks the dose. Semaglutide 2.4 mg produces about 15% mean weight loss at 68 weeks. The 1.0 mg arm produced about 6%. The 0.5 mg arm was not studied for weight loss in adults with obesity. Extrapolating below 0.5 mg is guesswork.
• Maintenance case series. Biermann et al, 2026, followed patients who tapered after reaching goal weight, showed that reduced-frequency dosing preserved most of the loss in a small cohort ^[4]. This is the strongest published signal in favor of any microdosing pattern, and it is a case series, not a randomized trial.
• Inflammation and metabolic markers. Standard-dose GLP-1 cuts C-reactive protein roughly 40 to 50% in the STEP trials. Whether sub-label doses produce a clinically meaningful anti-inflammatory effect is unknown.
• Side effect data. Dose-response also runs in the other direction. Lower doses produce fewer GI side effects in every controlled comparison. That is real, predictable, and the main reason microdosing appeals to people.

The cleanest summary: lower side effects are nearly guaranteed, lower efficacy is nearly guaranteed, and where the two curves cross for any individual patient is unknowable from current data.

Microdosing versus standard dosing

Microdosing for inflammation and autoimmune conditions

A subset of the microdosing community uses sub-label GLP-1 doses not for weight loss but for the anti-inflammatory effects. GLP-1 receptors sit on immune cells, and standard doses of semaglutide reduce inflammatory markers like CRP across multiple trials. People with Hashimoto's thyroiditis, psoriasis, and other inflammatory conditions sometimes report symptomatic improvement on doses of 0.05 to 0.25 mg semaglutide weekly. The mechanism is plausible. The evidence is anecdotal. No prescribing guideline supports the practice.

For Hashimoto's specifically, the rationale is that GLP-1 may reduce autoimmune-driven inflammation and assist with the insulin resistance that often runs alongside the disease. There is no trial of GLP-1 at any dose as primary therapy for Hashimoto's. Levothyroxine remains the standard of care. If you are exploring microdosing for an autoimmune condition, the conversation belongs with the endocrinologist managing that condition, not a telehealth subscription service.

The compounding problem

Most microdosing happens through compounded GLP-1 because the brand pens do not deliver sub-label doses. The Ozempic 0.25 mg pen has fixed dose marks, and the FDA-approved Zepbound vials are labeled single-use. Compounding lets a pharmacy ship a multi-dose vial at a custom concentration that an insulin syringe can draw to any volume.

The trade-off: compounded GLP-1 is not FDA approved. The semaglutide and tirzepatide shortages that legally permitted broad compounding ended in 2025. Pharmacies can still compound for specific patient needs (allergies, dose variations a prescriber has documented), but the legal landscape narrowed, and the quality varies pharmacy to pharmacy. The FDA has warned about contamination and overdose cases tied to compounded GLP-1.

If you go this route, the questions to ask the pharmacy are: are you a 503A or 503B compounder, what is the concentration on the vial in mg/mL, what is the beyond-use date, and what is the source of the active pharmaceutical ingredient (USP-grade and from an FDA-registered facility, or research-grade from a peptide supplier).

Who should not microdose

There are clear cases where the sub-label approach is the wrong tool.

• Type 2 diabetes that requires medication. Microdose semaglutide does not produce the A1c reductions that the labeled dose does. If your reason for being on a GLP-1 is glycemic control, dropping below 0.5 mg weekly likely undertreats the condition.
• BMI in the obesity range with weight-related complications. The trials supporting the obesity indication used full doses. Microdosing for a patient who qualifies for full-dose therapy is, on current evidence, undertreating obesity.
• People starting GLP-1 for the first time. The case for microdosing is strongest in maintenance, weakest in initiation. People new to these drugs have no baseline for how their body will respond, and the standard titration schedule was designed precisely to manage that.
• Anyone using a compounded product from an unverified source. This is not about the dose, it is about the supply chain.

The defensible cases: post-weight-loss maintenance under physician supervision, severe GI intolerance to standard doses where stopping the drug entirely is the alternative, and selected off-label use for inflammation or other indications that the patient and a knowledgeable clinician have agreed is worth trying despite the evidence gap.

What the FDA labels actually say

The FDA labels for Ozempic, Wegovy, Mounjaro, and Zepbound specify a single titration schedule each ^[1][2][3]. They do not contemplate sub-label dosing, dose splitting, or extended intervals. The labels also note that Zepbound and Mounjaro pens and single-dose vials are preservative-free and approved for single use only, which is why Lilly has stated that microdosing of those products raises contamination risk.

None of this makes off-label prescribing illegal. Physicians prescribe off-label all the time, and microdosing falls within that prerogative when a clinician documents a medical rationale. But "off-label" is not the same as "evidence-based." A prescriber who writes a microdose protocol is making a clinical judgment in the absence of trial data, which is a higher-stakes call than prescribing the approved regimen.

Practical checklist before microdosing

1. Confirm there is a real reason microdosing fits your situation. Maintenance, intolerance, inflammation, cost. "I saw it on TikTok" is not on the list.
2. Work with a prescriber who has obesity medicine experience. Not a script-mill telehealth provider you never speak to.
3. If you use a compounded product, get the concentration in mg/mL in writing on the vial label. Recheck at every refill.
4. Calculate your dose in mg and your draw in units. Write it down. Read it before every injection.
5. Track outcomes. Weight, waist, A1c if relevant, side effects. A microdose protocol with no measurable benefit at three months is failing.
6. Plan an exit. If you are microdosing as maintenance, decide in advance what happens if you regain weight or if symptoms return.

Common questions about GLP-1 microdosing

What is microdosing GLP-1?

Taking a GLP-1 receptor agonist at a dose below the FDA-approved titration schedule, often 0.05 to 0.125 mg semaglutide weekly instead of the labeled 0.25 mg start.

Does GLP-1 microdosing work for weight loss?

Anecdotally yes, clinically unproven. The published trials used full doses. Lower doses produce smaller weight loss on average, and the data on sub-label doses is limited to case series.

Is microdosing GLP-1 safe?

Lower side effects are predictable, but safety long term has not been studied. Risks include contamination from compounded products, dosing errors, and undertreatment of obesity or diabetes.

What is a GLP-1 microdosing chart for semaglutide?

A common protocol: 0.05 mg weekly for weeks 1 to 4, 0.1 mg weeks 5 to 8, 0.2 mg weeks 9 to 12. Off-label and not endorsed by Novo Nordisk.

How do you microdose GLP-1?

Most people use a compounded multi-dose vial from a 503A pharmacy and draw small volumes with a U-100 insulin syringe. Brand pens do not deliver sub-label doses.

What is the lowest GLP-1 dose for long-term use?

There is no established floor. Reported maintenance regimens include 0.05 to 0.25 mg semaglutide weekly or every two weeks. The label-approved minimum continuous-use dose is the starter step.

Can microdosing GLP-1 help with weight maintenance?

The Biermann 2026 case series suggests reduced-frequency dosing can preserve weight loss in patients who already hit their goal on standard doses. The data is preliminary but the most positive signal so far.

Does low-dose GLP-1 reduce inflammation?

Standard-dose semaglutide cuts CRP by 40 to 50% in the STEP trials. Whether microdoses produce the same anti-inflammatory effect is unknown.

Can I microdose GLP-1 for Hashimoto's?

Some patients report symptomatic improvement, but no trial supports GLP-1 at any dose as primary therapy for Hashimoto's. Levothyroxine remains the standard of care. Discuss with your endocrinologist.

How does microdosing compare to standard dosing?

Standard dosing has strong trial data, higher efficacy, more side effects, and higher cost. Microdosing has weaker evidence, lower efficacy, fewer side effects, and often lower cost. The trade-off depends on the goal.

The honest summary

If you are starting a GLP-1 for active weight loss or for diabetes, the labeled regimen is what has the data behind it. Microdosing in that scenario trades known benefit for unknown benefit, and the math rarely favors the patient.

If you have already lost the weight on a standard dose and want to maintain it, the case for stepping down is real and a recent case series supports it. Work with a clinician who is paying attention.

If you are using a GLP-1 for an off-label reason like inflammation or appetite quieting, microdosing is one of several reasonable approaches, but you are operating in a data desert. Anyone selling you certainty about sub-label dosing is selling you something other than evidence.

The labels exist for a reason. So does off-label prescribing. Knowing which side of that line you are on, and why, is the whole point.